1-8 of 8
Peter Schafer
Close
Sort by
Journal Articles

IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM

Shirong Li, Rekha Pal, Sara A. Monaghan, Peter Schafer, Hongjiao Ouyang, Markus Mapara, Deborah L. Galson, Suzanne Lentzsch
Journal: Blood
Blood (2011) 117 (19): 5157–5165.
https://doi.org/10.1182/blood-2010-10-314278
Published: 2011
Includes: Supplemental data
Journal Articles

C/EBPb Is a Critical Mediator of Resistance to IMiD® Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation

Shirong Li, PhD, Rekha Pal, PhD, Sara Monaghan, MD, Peter Schafer, PhD, Hongjiao Ouyang, DDS, PhD, Markus Y Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 135.
https://doi.org/10.1182/blood.V116.21.135.135
Published: 2010
Journal Articles

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia

Rekha Pal, Sara A. Monaghan, Andrea Cortese Hassett, Markus Y. Mapara, Peter Schafer, G. David Roodman, Margaret V. Ragni, Lynn Moscinski, Alan List, Suzanne Lentzsch
Journal: Blood
Blood (2010) 115 (3): 605–614.
https://doi.org/10.1182/blood-2009-05-221077
Published: 2010
Includes: Supplemental data
Journal Articles

The Anti-Proliferative Effect of Lenalidomide On MM Cells in Vitro Is Ameliorated by Prior Exposure to Pomalidomide, An Agent with Activity against Lenalidomide Resistant MM Cells.

Mary Adams, Peter Schafer, J. Blake Bartlett
Journal: Blood
Blood (2009) 114 (22): 4926.
https://doi.org/10.1182/blood.V114.22.4926.4926
Published: 2009
Journal Articles

Lenalidomide Enhancement of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Is Mediated by Granzyme B and FasL and Is Associated with Modification of SHIP-1, PLC-g2 and pERK and Enhanced Chemokine Production.

Lei Wu, MD, Mary Adams, MS, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, Blake J. Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 4885.
https://doi.org/10.1182/blood.V110.11.4885.4885
Published: 2007
Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2007) 110 (11): 3473.
https://doi.org/10.1182/blood.V110.11.3473.3473
Published: 2007
Journal Articles

Lenalidomide Strongly Enhances Natural Killer (NK) Cell Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) of Rituximab Treated Non-Hodkin’s Lymphoma Cell Lines In Vitro .

Lei Wu, MD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD
Journal: Blood
Blood (2006) 108 (11): 3714.
https://doi.org/10.1182/blood.V108.11.3714.3714
Published: 2006
Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD
Journal: Blood
Blood (2005) 106 (11): 3959.
https://doi.org/10.1182/blood.V106.11.3959.3959
Published: 2005